Labiotech.eu

News and Trends 16 Aug 2022

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Merck, also known as MSD outside the U.S. and Canada, and Orna Therapeutics, a biotech company working on a new investigational class of engineered circular RNA (oRNA) therapies, are to collaborate on discovering, developing, and commercializing multiple programs, including vaccines and therapeutics, in the areas of infectious diseases and oncology. Under the terms of the […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

Patient dosed in phase 1 trial evaluating ATG-018 treatment

News and Trends 16 Aug 2022

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

The first patient has been dosed in a phase 1 trial evaluating a monotherapy treatment in people with advanced solid tumors and hematologic malignancies in Australia. Antengene Corporation Ltd., is running the ATRIUM trial, a phase 1 multi-center, open-label, dose-finding study of monotherapy ATG-018. Safety and tolerability of ATG-018 The primary objective of the study […]

August 16, 2022 - 3 minutesmins - By Liza Laws

ADC Therapeutics announces $175M loan from Owl Rock

News and Trends 16 Aug 2022

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

ADC Therapeutics has announced a series of major strategic transactions involving hundreds of millions of dollars allowing it to advance its lead candidate and pipeline drugs. The Swiss company has entered into a new $175 million senior secured loan with certain funds of Owl Rock – a division of Blue Owl Capital, Inc. and funds […]

August 16, 2022 - 3 minutesmins - By Liza Laws

PBC clinical trials: Gannex doses first patient

News and Trends 16 Aug 2022

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Pneumagen embarks on phase 2 proof of concept influenza study

Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Following a positive opinion from the European Medicines Agency (EMA), the European Commission (EC) has granted orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 for the treatment of chondrosarcoma. “We are highly optimistic about the potential of INBRX-109 in chondrosarcoma to address a high unmet medical need,” said Inhibrx CEO, Mark Lappe. “The positive […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Genentech lymphoma treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA […]

August 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Remedium raises more funds for osteoarthritis gene therapy candidate

Remedium Bio, Inc., a biotech company developing novel gene therapies, has closed more than $2.3 million in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss. The study is being undertaken in a collaboration with Tufts University […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

In Depth 15 Aug 2022

Can phage therapy answer the booming antibiotic resistance problem?

Antibiotic-resistant superbugs cause a large number of deaths around the world each year, but effective new antibiotics are thin on the ground. Could bacteria-eating phage viruses be the answer to this problem? The COVID-19 pandemic has received blanket news coverage over the past couple of years, however, it still pales in comparison to the threat […]

August 15, 2022 - 8 minutesmins - By David Cox

News and Trends 15 Aug 2022

Opthea secures up to $170M in financing for wet AMD treatment

Opthea Limited, a clinical-stage biopharma company developing novel therapies to treat highly prevalent and progressive retinal diseases, has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related […]

August 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Approval for Small Pharma major depressive disorder clinical trial

Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Scientists develop gel from spider silk proteins for biomedical applications

Researchers at Karolinska Institutet in Sweden and the Swedish University of Agricultural Sciences have discovered spider silk proteins can be fused to biologically active proteins and be converted into a gel at body temperature. One of the goals is to develop an injectable protein solution that forms a gel inside the body, which could be […]

August 15, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Merck puts up to $37B into Orna Therapeutics circular RNA collaboration

Patient dosed in phase 1 trial evaluating treatment for those with tumors and malignancies

ADC Therapeutics announces series of financial moves including $175M loan from Owl Rock

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

Pneumagen embarks on phase 2 proof of concept influenza study

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Genentech lymphoma treatment gets FDA approval

Remedium raises more funds for osteoarthritis gene therapy candidate

Can phage therapy answer the booming antibiotic resistance problem?

Opthea secures up to $170M in financing for wet AMD treatment

Approval for Small Pharma major depressive disorder clinical trial

Scientists develop gel from spider silk proteins for biomedical applications

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!